World Health Organization Group III pulmonary hypertension

Progress in Cardiovascular Diseases

Volumn 55, Issue 2, 2012, Pages 119-127

  Poor, Hooman D ^a   Girgis, Reda ^b   Studer, Sean M ^c  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b SPECTRUM HEALTH   (United States)

^c NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

COPD; Hypoxic pulmonary vasoconstriction; ILD; OSA; Pulmonary hypertension

Indexed keywords

ACETAZOLAMIDE; AMBRISENTAN; ANTIINFLAMMATORY AGENT; BOSENTAN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMMUNOSUPPRESSIVE AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAVASTATIN; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SIMVASTATIN; VASODILATOR AGENT;

ALTITUDE DISEASE; ARTICLE; BARIATRIC SURGERY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HEART CATHETERIZATION; HEART HEMODYNAMICS; HUMAN; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LUNG EMPHYSEMA; LUNG FIBROSIS; OBESITY HYPOVENTILATION SYNDROME; OXYGEN THERAPY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PULMONARY HYPERTENSION; SARCOIDOSIS; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; TREATMENT DURATION; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION;

ANOXIA; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY WEDGE PRESSURE; WORLD HEALTH ORGANIZATION;

EID: 84866628793     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2012.08.003     Document Type: Article

References (98)

1. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009 Jun 30, 54(1 Suppl):S43-S54.
2. Naeije R., Barbera J.A. Pulmonary hypertension associated with COPD. Crit Care 2001, 5:286-289.
3. Minai O.A. Pulmonary hypertension in COPD: a review of the literature. PVRI Review 2009, 1:20-26.
4. Nathan S.D., Noble P.W., Tuder R.M. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007, 175:875-880.
5. Barnett C.F., Bonura E.J., Nathan S.D., et al. Treatment of sarcoidosis-associated pulmonary hypertension; a two-center experience. Chest 2009, 135(6):1455-1461. [Epub 2008 Dec 31].
6. Minai O.A., Nathan S.D., Hill N.S., et al. Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns. Respir Med 2010, 104(5):741-748. [Epub 2010 Jan 21].
7. Hill N, Minai OA, Nathan SD. Advances in pulmonary hypertension. Autumn 2009;8(3)163-171.
8. King T.E., Tooze J.A., Schwarz M.I., et al. Predicting survival in idiopathic pulmonary fibrosis: Scoring system and survival model. Am J Respir Crit Care Med 2001, 164:1171-1181.
9. Hallstrand T.S., Boitano L.J., Johnson S.C., et al. The timed walk test as a measure of severity and survival and idiopathic pulmonary fibrosis. Eur Respir J 2005, 25:96-103.
10. Lama V.N., Flaherty K.R., Toew G.B., et al. Prognostic value of desaturation during a 6 minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:1084-1090.
11. Bishop J.M., Cross K.W. Physiological variables and mortality in patients with various categories of chronic respiratory disease. Bull Eur Physiopathol Respir 1984, 20:495-500.
12. Hyduk A, Crift JB, Ayala C, et al. Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveillance Summaries 2005; 54, S-5: 1-28.
13. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension and COPD. Eur Respir J 2008, 32:1371-1385.
14. McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence based clinical practice guidelines. Chest 2004, 126:14s-34s.
15. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus documented on pulmonary hypertension. J Am Coll Cardiol 2009, 53:1573-1619.
16. Nathan S.D. Pulmonary hypertension and interstitial lung disease. Intl J Clin Pract 2008, 160:21-28.
17. Ward J.P.T., McMurtry I.F. Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr Opin Pharmacol 2009, 9:287-296.
18. Moudgil R., Michelakis E.D., Archer S.L. Hypoxic pulmonary vasoconstriction. J Appl Physiol 2005, 98:390-403.
19. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30(20):2493-2537.
20. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334(5):296-302.
21. Olschewski H., Simonneau G., Galiè N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347(5):322-329.
22. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165(6):800-804.
23. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346(12):896-903.
24. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353(20):2148-2157.
25. Zhao L., Mason N.A., Morrell N.W., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104(4):424-428.
26. Hales C.A. The site and mechanism of oxygen sensing for the pulmonary vessels. Chest 1985, 88(4 Suppl):235S-240S.
27. Minai O.A., Nathan S.D., Hill N.S., et al. Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns. Respir Med 2010, 104(5):741-748.
28. Ferreira A., Garvey C., Connors G.L., et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009, 135(2):442-447.
29. Ries A.L., Bauldoff G.S., Carlin B.W., et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007, 131(5 Suppl):4S-42S.
30. Fox B.D., Kassirer M., Weiss I., et al. Ambulatory rehabilitation improves exercise capacity in patients with pulmonary hypertension. J Card Fail 2011, 17(3):196-200.
31. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008, 32(5):1371-1385.
32. Weitzenblum E. Chronic cor pulmonale. Heart 2003, 89(2):225-230.
33. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789.
34. Sutherland E.R., Cherniack R.M. Management of chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2689-2697.
35. Santos S., Peinado V.I., Ramírez J., et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002, 19(4):632-638.
36. Pride N.B. Smoking cessation: effects on symptoms, spirometry and future trends in COPD. Thorax 2001, 56(Suppl. 2):ii7-ii10.
37. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981, 1(8222):681-686.
38. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980, 93(3):391-398.
39. Weitzenblum E., Sautegeau A., Ehrhart M., et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985, 131(4):493-498.
40. Zielinski J., Tobiasz M., Hawryłkiewicz I., et al. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998, 113(1):65-70.
41. 2 above 60mm Hg. Am Rev Respir Dis 1992, 145(5):1070-1076.
42. Chaouat A., Weitzenblum E., Kessler R., et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999, 14(5):1002-1008.
43. Gorecka D., Gorzelak K., Sliwiński P., et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997, 52(8):674-679.
44. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
45. Bailey WC. Effectiveness of Long-term Oxygen Therapy in Treating People With Chronic Obstructive Pulmonary Disease (The Long-term Oxygen Treatment Trial [LOTT]) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-2012. Accessed August 29, 2012. http://www.clinicaltrials.gov/ct2/show/NCT00692198?term=NCT00692198&rank=1.
46. Minai O.A., Chaouat A., Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010, 137(6 Suppl):39S-51S.
47. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351(14):1425-1436.
48. Holverda S., Rietema H., Bogaard H.J., et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther 2008, 21(3):558-564.
49. Blanco I., Gimeno E., Munoz P.A., et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010, 181(3):270-278.
50. Alp S., Skrygan M., Schmidt W.E., et al. Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm Pharmacol Ther 2006, 19(6):386-390.
51. Rietema H., Holverda S., Bogaard H.J.., et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008, 31(4):759-764.
52. Milara J., Gabarda E., Juan G., et al. Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries. Eur Respir J 2012, 39(4):927-938.
53. Valerio G., Bracciale P., Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009, 3(1):15-21.
54. Stolz D., Rasch H., Linka A., et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008, 32(3):619-628.
55. Jones K., Higenbottam T., Wallwork J. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest 1989, 96(4):784-789.
56. Archer S.L., Mike D., Crow J., et al. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996, 109(3):750-755.
57. Walmrath D., Schermuly R., Pilch J., et al. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997, 10(5):1084-1092.
58. Griffiths M.J., Evans T.W. Inhaled nitric oxide therapy in adults. N Engl J Med 2005, 353(25):2683-2695.
59. Adnot S., Kouyoumdjian C., Defouilloy C., et al. Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am Rev Respir Dis 1993, 148(2):310-316.
60. Germann P., Ziesche R., Leitner C., et al. Addition of nitric oxide to oxygen improves cardiopulmonary function in patients with severe COPD. Chest 1998, 114(1):29-35.
61. Vonbank K., Ziesche R., Higenbottam T.W., et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003, 58(4):289-293.
62. Weinberger B., Laskin D.L., Heck D.E., et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001, 59(1):5-16.
63. Dernaika T.A., Beavin M., Kinasewitz G.T. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010, 79(5):377-382.
64. Hernandez-Perera O., Pérez-Sala D., Navarro-Antolín J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101(12):2711-2719.
65. Wright J.L., Zhou S., Preobrazhenska O., et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011, 183(1):50-58.
66. Lee T.M., Chen C.C., Shen H.N., et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009, 116(6):497-505.
67. Criner G.J., Scharf S.M., Falk J.A., et al. Effect of lung volume reduction surgery on resting pulmonary hemodynamics in severe emphysema. Am J Respir Crit Care Med 2007, 176(3):253-260.
68. Fishman A., Martinez F., Naunheim K., et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003, 348(21):2059-2073.
69. Fell C.D., Martinez F.J. The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest 2007, 131(3):641-643.
70. Trad S., Amoura Z., Beigelman C., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006, 54(1):184-191.
71. Behr J., Ryu J.H. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008, 31(6):1357-1367.
72. Mittoo S., Jacob T., Craig A., et al. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease. Can Respir J 2010, 17(6):282-286.
73. Le Pavec J., Girgis R.E., Lechtzin N., et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011, 63(8):2456-2464.
74. Pitsiou G., Papakosta D., Bouros D. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration 2011, 82(3):294-304.
75. King T.E., Behr J., Brown K.K., et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177(1):75-81.
76. Gillies H. ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-2012.). Accessed August 29, 2012. http://www.clinicaltrials.gov/ct2/show/NCT00879229?term=NCT00879229&rank=1:NCT00879229.
77. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360(9337):895-900.
78. Corte T.J., Gatzoulis M.A., Parfitt L., et al. The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology 2010, 15(8):1226-1232.
79. Collard H.R., Anstrom K.J., Schwarz M.I., et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007, 131(3):897-899.
80. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman D.A., Schwarz M., et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363(7):620-628.
81. Minai O.A., Sahoo D., Chapman J.T., et al. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir Med 2008, 102(7):1015-1020.
82. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999, 160(2):600-607.
83. Blanco I., Ribas J., Xaubet A., et al. Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis. J Appl Physiol 2011, 110(3):638-645.
84. Jankowich M.D., Rounds S. Combined pulmonary fibrosis and emphysema sundrome; a review. Chest 2012, 141:222-231.
85. Usui K., Tanai C., Tanaka Y., et al. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology 2011, 16:326-331.
86. Cottin V., Le Pavec J., Prevot G., et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010, 35:105-111.
87. Giles T.L., Lasserson T.J., Smith B., et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006, (1):CD001106-CD.
88. Alchanatis M., Tourkohoriti G., Kakouros S., et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration 2001, 68(6):566-572.
89. Sajkov D., Wang T., Saunders N.A., et al. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2002, 165(2):152-158.
90. Arias M.A., García-Río F., Alonso-Fernández A., et al. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 2006, 27(9):1106-1113.
91. Xu X.Q., Jing Z.C. High-altitude pulmonary hypertension. Eur Respir Rev 2009, 18(111):13-17.
92. Rivera-Ch M., Huicho L., Bouchet P., et al. Effect of acetazolamide on ventilatory response in subjects with chronic mountain sickness. Respir Physiol Neurobiol 2008, 162(3):184-189.
93. Richalet J.P., Rivera M., Bouchet P., et al. Acetazolamide: a treatment for chronic mountain sickness. Am J Respir Crit Care Med 2005, 172(11):1427-1433.
94. Richalet J.P., Rivera M., Bouchet P., et al. Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment. Am J Respir Crit Care Med 2008, 177(12):1370-1376.
95. Seheult R.D., Ruh K., Foster G.P., et al. Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. Respir Physiol Neurobiol 2009, 165(2-3):123-130.
96. Aldashev A.A., Kojonazarov B.K., Amatov T.A., et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005, 60(8):683-687.
97. Shigemitsu H., Nagai S., Sharma O.P. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med 2007, 13:434-438.
98. Barnett C.F., Bonura E.J., Nathan S.D., et al. Treatment of sarcoidosis-associated pulmonary hypertension. Chest 2009, 135:1455-1461. [Epub 2008 Dec 31].